Spyre Therapeutics (SYRE) said Monday it started an underwritten public offering of up to $200 million of shares or pre-funded warrants.
Underwriters will be given an option for a 30-day period to buy up to an additional $30 million of shares, the company said.
All of the shares and warrants will be sold by Spyre, the company said, adding the offering is subject to market conditions.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。